Subscribe
The explosion of data regarding residual risk and contributions from LDL-P predicts an exciting future. Right now, treatment regimens are in flux awaiting further details on LDL-P interventions and a host of new drugs.
Residual Cardiovascular Risk: New Research on Particle Behavior
Type 2 Diabetes and Chronic Kidney Disease in an Elderly Woman: How Would You Treat?
Lipid-lowering Injectable Antibodies: The Next Big Thing?
The “Statin-Intolerant” Patient: Alternative Strategies for Primary Care
Jessica Ailani, MD, FAHS, FAAN; Paul G. Mathew, MD, DNBPAS, FAAN, FAHS
Asim V. Farooq, MD; Joann Kang, MD; Nita Lee, MD, MPH
Sanjai Rao, MD, DFAPA; Dawn I. Velligan, PhD
Jacob Sands, MD; Beth Sandy, MSN, CRNP, FAPO; Stephanie McDonald, FNP-BC, AOCNP
John F. Brandsema, MD; Abigail N. Schwaede, MD; Samuel J. Mackenzie, MD, PhD
Anil K. Agarwal, MD; Nissreen Elfadawy, MD, MSc, FASN
Glenn M. Chertow, MD, MPH; Anjay Rastogi, MD, PhD
Eytan M. Stein, MD; Marina Kremyanskaya, MD, PhD; Hannah Levavi, MD
Deborah Ristvedt, DO; Melissa Tawa, OD, FAAO
Daniel J. DeAngelo, MD, PhD; Claire Roddie, MD, PhD
Rami Komrokji, MD; Maen Hussein, MD